Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians

European Neuropsychopharmacology

Volumn 20, Issue 10, 2010, Pages 688-694

  Souza, Renan P ^a   Remington, Gary ^a,b   Chowdhury, Nabilah I ^a   Lau, Matthew K ^a   Voineskos, Aristotle N ^a   Lieberman, Jeffrey A ^c   Meltzer, Herbert Y ^d   Kennedy, James L ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

AIMS; Extrapyramidal symptoms; Genetics; Glycogen synthase kinase; Movement disorders; Pharmacogenetics

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA;

ADULT; ARTICLE; DISEASE SEVERITY; DNA POLYMORPHISM; EUROPEAN AMERICAN; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

ADULT; DISEASE PROGRESSION; DOPAMINE; DYSKINESIA, DRUG-INDUCED; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLYCOGEN SYNTHASE KINASE 3; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; YOUNG ADULT;

EID: 77956171015     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.05.002     Document Type: Article

References (27)

1. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
2. Beaulieu J.M., Gainetdinov R.R., Caron M.G. Akt/GSK3 signaling in the action of psychotropic drugs. Annu. Rev. Pharmacol. Toxicol. 2009, 49:327-347.
3. Bender R., Lange S. Multiple test procedures other than Bonferroni's deserve wider use. BMJ 1999, 318:600-601.
4. Beurel E., Jope R.S. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog. Neurobiol. 2006, 79:173-189.
5. Carmichael J., Sugars K.L., Bao Y.P., Rubinsztein D.C. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J. Biol. Chem. 2002, 277:33791-33798.
6. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet. Epidemiol. 2003, 25:115-121.
7. Gauderman W.J. Sample size requirements for matched case-control studies of gene-environment interaction. Stat. Med. 2002, 21:35-50.
8. Inkster B., Nichols T.E., Saemann P.G., Auer D.P., Holsboer F., Muglia P., Matthews P.M. Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder. Arch. Gen. Psychiatry 2009, 66:721-728.
9. Jope R.S., Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr. Drug Targets 2006, 7:1421-1434.
10. Kane J.M., Smith J.M. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch. Gen. Psychiatry 1982, 39:473-481.
11. Kang U.G., Seo M.S., Roh M.S., Kim Y., Yoon S.C., Kim Y.S. The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett. 2004, 560:115-119.
12. Kwok J.B., Hallupp M., Loy C.T., Chan D.K., Woo J., Mellick G.D., Buchanan D.D., Silburn P.A., Halliday G.M., Schofield P.R. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann. Neurol. 2005, 58:829-839.
13. Lahiri D.K., Nurnberger J.I. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991, 19:5444.
14. Little J., Higgins J.P., Ioannidis J.P., Moher D., Gagnon F., von Elm E., Khoury M.J., Cohen B., Davey-Smith G., Grimshaw J., Scheet P., Gwinn M., Williamson R.E., Zou G.Y., Hutchings K., Johnson C.Y., Tait V., Wiens M., Golding J., van Duijn C., McLaughlin J., Paterson A., Wells G., Fortier I., Freedman M., Zecevic M., King R., Infante-Rivard C., Stewart A., Birkett N. STrengthening the REporting of Genetic Association Studies (STREGA)-an extension of the STROBE statement. Genet. Epidemiol. 2009, 33:581-598.
15. Nyholt D.R. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am. J. Hum. Genet. 2004, 74:765-769.
16. Park S.W., Lee J.G., Kong B.G., Lee S.J., Lee C.H., Kim J.I., Kim Y.H. Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia. Psychiatry Clin. Neurosci. 2009, 63:433-439.
17. Roh M.S., Seo M.S., Kim Y., Kim S.H., Jeon W.J., Ahn Y.M., Kang U.G., Juhnn Y.S., Kim Y.S. Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Exp. Mol. Med. 2007, 39:353-360.
18. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 1982, 39:486-487.
19. Souza R.P., de Luca V., Remington G., Lieberman J.A., Meltzer H.Y., Kennedy J.L., Wong A.H. Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia. Psychopharmacology (Berl.) 2010, 210:347-354.
20. Souza R.P., Remington G., Lieberman J.A., Meltzer H.Y., Kennedy J.L., Wong A.H. Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia. Int. Clin. Psychopharmacol 2010, 10.1097/YIC.0b013e32833a5ff9.
21. Souza R.P., Romano-Silva M.A., Lieberman J.A., Meltzer H.Y., Wong A.H., Kennedy J.L. Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl.) 2008, 200:177-186.
22. Thelma B., Srivastava V., Tiwari A.K. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 2008, 9:1285-1306.
23. Wang W., Yang Y., Ying C., Li W., Ruan H., Zhu X., You Y., Han Y., Chen R., Wang Y., Li M. Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 2007, 52:1678-1684.
24. Weiss K.M., Clark A.G. Linkage disequilibrium and the mapping of complex human traits. Trends Genet. 2002, 18:19-24.
25. Zai C.C., Romano-Silva M.A., Hwang R., Zai G.C., Deluca V., Muller D.J., King N., Voineskos A.N., Meltzer H.Y., Lieberman J.A., Potkin S.G., Remington G., Kennedy J.L. Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. Schizophr. Res. 2008, 106:248-252.
26. Zai C.C., Tiwari A.K., Basile V., De Luca V., Muller D.J., King N., Voineskos A.N., Remington G., Meltzer H.Y., Lieberman J.A., Potkin S.G., Kennedy J.L. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics J. 2009, 9:168-174.
27. Zai C.C., Tiwari A.K., De Luca V., Muller D.J., Bulgin N., Hwang R., Zai G.C., King N., Voineskos A.N., Meltzer H.Y., Lieberman J.A., Potkin S.G., Remington G., Kennedy J.L. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur. Neuropsychopharmacol. 2009, 19:317-328.